Evotec-Partner Tubulis Announces Strategic License Agreement with Bristol Myers Squibb

Evotec-partner Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (“ADCs”).

Read More